Lower your blood pressure naturally
(WGHP) — You go to the doctor's office, and one of the first things they'll do is take your blood pressure. It's a simple procedure that takes just seconds but knowing whether you have high blood pressure can save your life.
In Successful Aging, we learn about the dangers of undiagnosed hypertension and how you can help lower your numbers naturally.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
How Is Hologic's Stock Performance Compared to Other Health Care Equipment Stocks?
With a market cap of $14.3 billion, Hologic, Inc. (HOLX) is a Massachusetts-based medical technology firm, primarily focused on women's health. The company develops, manufactures, and sells a comprehensive suite of solutions, including molecular diagnostics, medical imaging systems, and surgical devices Companies worth $10 billion or more are generally described as 'large-cap stocks,' and Hologic fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the medical instruments & supplies industry. The company benefits from robust innovation, supported by over 7,000 patents, which fuels its proprietary technologies and product differentiation. Its diagnostics segment, particularly in molecular testing, has shown strong growth, positioning Hologic well in the expanding global healthcare market. 2 Outstanding Stocks Under $50 to Buy and Hold Now Nvidia's Bringing Sovereign AI to Germany. Should You Buy NVDA Stock Here? A $1 Billion Reason to Buy MicroStrategy Stock Here Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. However, HOLX shares have retreated 24.5% from their 52-week high of $84.67 touched on Aug. 9, 2024. Meanwhile, HOLX stock has surged 3.2% over the past three months, surpassing the SPDR S&P Health Care Equipment ETF's (XHE) 4.8% plunge over the same time frame. HOLX stock has plummeted 11.3% on a YTD basis and 10.5% over the past 52 weeks, compared to XHE's 10.6% dip in 2025 and a 6.3% fall over the past year. The stock has remained consistently below its 200-day moving average since early December last year, but has climbed above its 50-day moving average since late May. On May 27, HOLX shares surged more than 14%, leading S&P 500 gainers, after reports emerged that TPG Inc. (TPG) and Blackstone Inc. (BX) made (and were turned down on) a non-binding ~$16 billion takeover bid, valuing the company at $70–$72 per share. The stock's rally reflected investor optimism and underscored the premium valuation placed on its leadership in women's health and diagnostic capabilities. In the competitive healthcare equipment industry, top rival, Align Technology, Inc.'s (ALGN) 13.7% drop on a YTD basis and 25.7% decline over the past year trails HOLX's losses in the same time frames. Among the 19 analysts covering the HOLX stock, the consensus rating is a 'Moderate Buy.' Its mean price target of $68.27 suggests a 6.7% upside potential from current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Muscles, fats and simple blood test can predict menopausal women's health
SINGAPORE – A simple blood test can predict which woman will have less muscle and will be walking more slowly later in life. It is also practical and cheaper than current methods of measuring muscle, such as the current gold standard magnetic resonance imaging scans or strength tests, which are also more time-consuming. This new insight from a longitudinal cohort study of midlife women in Singapore shone light on how muscle strength, visceral fat and their association with physical decline after menopause can potentially lead to downstream health impacts among women here. Researchers from the National University Hospital (NUH) and National University of Singapore (NUS) found that women with a lower creatinine-to-cystatin C ratio (CCR) – a marker derived from blood tests – had less muscle and walked more slowly as they age. Creatinine is a by-product of normal muscle function and energy use, and a higher level indicates higher skeletal muscle mass or poor kidney function. Cystatin C is a protein produced by the body's cells that is filtered out by the kidneys. A normal cystatin C level rules out poor kidney function. A low CCR of under 8.16 was associated with a lower muscle volume of 0.35 litres in the thigh, and a slower gait of 0.049m a second. This suggested that CCR could be a useful early warning sign for age-related muscle loss, which may lead to falls, frailty and reduced quality of life. The findings were published in Menopause, a monthly peer-reviewed journal, in March. The scientists involved in the study are from the Integrated Women's Health Programme (IWHP) at NUH and the NUS Yong Loo Lin School of Medicine. The IWHP was initiated to identify and address the healthcare needs of midlife Singaporean women. It recruited a cohort of 1,200 Chinese, Malay and Indian women aged 45 to 69 between 2014 and 2016 – about 70 per cent of whom were post-menopausal. Their health metrics were then tracked over time. In the first study based on this cohort, published in international journal Maturitas in October 2023, the researchers shared a ranking of menopausal symptoms – with joint and muscular discomfort found to be the most reported symptom among women in Singapore. Called arthralgia, it had moderate or severe impact on a third of the midlife women of the cohort. A subsequent study, published in the Diabetes, Obesity and Metabolism journal in October 2024, found that women with both weak muscle strength and high levels of visceral fat – the deep belly fat around the internal organs – had the highest risk of developing prediabetes or type 2 diabetes. Their risk was 2.63 times higher than that of women who had normal muscle strength and lower fat levels. Having just one of these conditions also increased their risk, though to a lesser degree. The risk from having high visceral fat alone is 1.78 times higher. Among those with weak muscle strength, women with high visceral fat faced 2.84 times as much risk compared with those with low visceral fat. Explaining the impetus for the study, IWHP lead Yong Eu Leong said: 'Muscle... burns up fat. What about those who have weak muscles? Does it affect the risk for diabetes in the future?' The cohort's initial muscle and visceral fat measurements served as a baseline for researchers to track changes over the years. Researchers then analysed how changes in fat and muscle measurements taken about six years later – by then, about 90 per cent of the women were post-menopausal – related to whether women had developed diabetes. Professor Yong, who also heads the division of benign gynaecology in the Department of Obstetrics and Gynaecology at NUH, noted that a large proportion of women in Singapore are 'skinny fat', where their body mass index is within the normal range, but that they have high levels of visceral fat and low muscle mass. 'One way (to know what your risks are) is to measure your walk and the speed at which you walk. If you cannot walk fast and straight, then your health is not so good. We wanted to see if we can develop a test that can predict gait speed. We wanted to look at molecules that actually measure muscle functions,' he said. 'These findings validated our previous (IWHP) research that showed that women should not just focus on weight loss, but on building muscle strength through exercise for diabetes prevention,' Prof Yong said. One participant of the IWHP, administrative assistant Sabarina Jumarudin, is living proof of the findings. The 59-year-old grandmother used to weigh 93kg and suffered from sleep apnoea. Since undergoing bariatric surgery at NUH in 2018, a procedure that modifies the digestive system to help people with obesity lose weight, she has lost more than 30kg. Mindful of keeping her weight down, Madam Sabarina walks to the MRT station every day instead of taking the shuttle service, and takes the stairs instead of the escalator to catch the train. 'On my way home, I usually take a longer route to ensure I clock at least 10,000 steps a day, and practise stretching and breathing exercises to strengthen my core,' she said. 'I realised that small but consistent changes do make a big impact on my health, so I do what I can on a daily basis, and it gives me confidence to not only stay healthy physically and mentally but also stave off diabetes,' she added. Source: The Straits Times © SPH Media Limited. Permission required for reproduction Discover how to enjoy other premium articles here
Yahoo
a day ago
- Yahoo
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib CHICAGO and FORT WORTH, Texas, June 20, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) ('Actuate' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced biomarker data from a recent poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metastatic pancreatic adenocarcinoma (mPDAC). The study demonstrated the use of machine learning and statistical models to predict overall survival (OS) based on pre-dose plasma biomarkers. The poster described an analysis of 40 cytokines, chemokines, soluble cell receptors, and growth factors (CCSGs) from plasma samples obtained prior to treatment from all patients enrolled in Actuate-1801 Part 3B. The analysis identified 7 biomarkers as uniquely significant predictors of favorable survival in the elraglusib-treated cohort, including one, CXCL2, with an inverse survival trend compared to the GnP control arm. This indicates that in patients not treated with elraglusib, high CXCL2 was unfavorable, but this trend is reversed with elraglusib treatment, highlighting the potential of elraglusib to favorably affect the immune microenvironment. Univariate analysis revealed strong predictive performance with CXCL2 emerging as a consistently reliable biomarker for survival across multiple cross-validation analyses. Elevated levels of CXCL2 and TRAIL were associated with improved OS, while lower levels of CCL3, IL-1α, IL-18, TGF-β, and TRAIL R3 were similarly linked to better survival. These signatures were combined into multivariate machine learning models that accurately predicted patients who would survive for greater than one year if treated with elraglusib and GnP. 'These results represent an important advance in our biomarker strategy,' said Daniel Schmitt, President & Chief Executive Officer of Actuate. 'They support the ability to use simple, non-invasive blood-based markers to potentially identify patients more likely to benefit from elraglusib. The pre-dose biomarker signatures identified in the 1801 Part 3B study, particularly involving high CXCL2 and low TGF-β, CCL3, and IL-18, which were all associated with a survival benefit, suggests that elraglusib may exert pleiotropic immunomodulatory effects regulating cytotoxic T cells, NK cells and cells of the myeloid lineage including macrophages and neutrophils. Crosstalk between components of the immune system support the growing body of evidence that elraglusib enhances immune response mechanisms critical to its antitumor efficacy.' 'The application of unbiased mathematical and machine learning models allowed us to pinpoint the strongest biomarker signals free from pre-conceived notions of elraglusib's mechanisms. What is so exciting about this project is that the unbiased approach aligns with prior mechanistic studies. The congruence of our clinical data analytics and the preclinical research combined with the strength of our predictive models gives us confidence that these biomarkers could be extremely beneficial in identifying the right patients at the right time,' said Taylor Weiskittel, MD, Ph.D., the lead author on this study. 'We look forward to applying this approach to guide the development of elraglusib in mPDAC as well as other advanced cancer indications in the future.' The company plans to test the identified biomarkers prospectively in future trials. Additional efforts will focus on optimizing sequential univariate combinations for patient stratification, refining multivariate machine learning models for predictive accuracy, and comparing these approaches head-to-head. About Actuate Therapeutics, Inc. Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate's lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function. For additional information, please visit the Company's website at Forward-Looking Statements This press release contains forward-looking statements about us, including our and other parties' clinical trials and development plans, and our industry. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'ongoing,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would,' or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that preliminary and unpublished data including biomarker studies may be subject to change and further interpretation following the availability of more data or following a more comprehensive review of the data and should not be relied upon as a final analysis; clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies, early clinical trials, machine learning and predictive modeling are not necessarily predictive of future results and may not correlate with improved responses, and elraglusib may not achieve positive clinical results or favorable preclinical results or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose for such development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities, including because our financial condition raises substantial doubt as to our ability to continue as a going concern and we require additional capital to finance our operations beyond the second quarter of fiscal year 2025, and a failure to obtain this necessary capital in the near term on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading 'Item 1A. Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 15, 2025, and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events. Investor Contact Mike MoyerManaging DirectorLifeSci Advisors, LLCmmoyer@ Media Contact Ignacio Guerrero-Ros, Ph.D., or David SchullRusso Partners, 717-2310 or (646) 942-5604Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
